Vesivax vaccine formulation against neisseria gonorrhoeae
Ended Project Grant Awarded Last action
- Award ID
- R43AI167312
- Recipient
-
Molecular Express, Inc. UEI R1JMHFESEKD5
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $899,375
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date
- Originally
- Place of performance
- California, USA
Award details come from USAspending.gov.
Description
- Abstract
- The principal goal of this project is to develop a vesivax®-based vaccine against neisseria gonorrhoeae (NG). The studies proposed in this sbir phase I application will be focused on CO-formulating an newly identified surface-displayed outer membrane NG protein, mtre, with various immunostimulatory adjuvant molecules (IAMS) in the vesivax® liposomal platform. We will characterize the immunogenicity of these vesivax®-mtre-IAM formulations in mice, and select for the best candidates to be further evaluated in a novel mouse upper reproductive tract NG infection model. These studies will elucidate the immunological profile in a vaccine that will correlate with protective immunity against NG.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $299,779 | |
| Amendment | $299,779 | |
| Original award | $299,817 |
Quick answers
Who received award R43AI167312?
R43AI167312 was awarded to Molecular Express, Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on February 18, 2022.
How much is award R43AI167312 worth?
$899,375 has been obligated on R43AI167312.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award